# ViewsIQ Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viewsiq

- Industry: Medical Devices & Equipment
- Headquarters: Vancouver, Canada
- Website: www.viewsiq.ca
- Total disclosed funding: $0.1M
- Latest round: Seed (Jul 15, 2013)
- Investors on record: 1

## About

ViewsIQ Corporation offers advanced digital pathology solutions, enhancing diagnostic accuracy through innovative software technology. Its flagship product, Panoptiq™, supports high-resolution imaging essential for clinical microbiology applications.ViewsIQ Corporation operates from Vancouver, Canada, specializing in digital pathology solutions. Founded by H. L. and currently led by CEO H. L. and Kenny To, the company has secured a total of two funding deals, most recently raising USD 0.50 mn in a Seed round from Genome Canada on December 5, 2016. The company has not undergone any notable pivots or structural changes since its inception.ViewsIQ Inc. specializes in advanced digital pathology solutions, with its flagship product being the Panoptiq™ platform. Released in 2015, this software facilitates the use of high-resolution, oil-immersion lenses and supports the embedding of Z-stacks, crucial for achieving the necessary resolution in clinical microbiology. The Panoptiq system is designed to enhance the efficiency of various applications, including cytology, fine needle aspiration (FNA), frozen sections, and tumor board education. This comprehensive tool is utilized by a diverse client base that includes healthcare institutions such as UH Cleveland Medical Center, Nagasaki University, and Nikko Memorial Hospital & Hokkaido Cancer Center. The company caters to customers primarily in North America and Asia, with a noted presence in Japan, where affiliate partner sites benefit from its digital imaging capabilities.ViewsIQ Inc. generates revenue through subscription-based models and direct sales of its proprietary software, Panoptiq™. Clients, primarily healthcare organizations and educational institutions, engage with the company for tailored demonstrations and subsequent implementation of the software into their laboratory settings. Transactions typically involve the purchase of software licenses, which may include ongoing support and updates as part of the subscription package. The company's pricing structure is designed to accommodate various customer needs, focusing on the integration of advanced imaging technology into clinical workflows. This approach ensures that users can leverage Panoptiq™ for optimal results in digital cytology and related applications, thereby enhancing diagnostic accuracy and operational efficiency within their respective practices.ViewsIQ Corporation plans to further develop its Panoptiq™ platform with upcoming features aimed at enhancing performance and user experience, though specific release dates have not been disclosed. The company aims to expand its reach into international markets, particularly in Europe and South America, by the end of 2024. The recent Seed funding of USD 0.50 mn will be utilized to support these product enhancements and market expansion strategies.

## Funding rounds

- Seed, Jul 15, 2013, $0.1M — BDC Capital

## Investors

- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Seed